Introduction
The majority of antileukemic therapies involve systemic administration of chemotherapeutics. However, curative chemotherapeutic strategies are frequently accompanied by severe and long-term adverse complications that compromise the quality of life. Among the side-effects of chemotherapy there is a transient immunosuppression that often compromises not only the immune responses against microbial pathogens but may also favor survival of residual leukemic cells that might be the cause of relapse. 1, 2 Moreover, because of frequent dramatic toxicities the effectiveness of chemotherapy seems to have approached its therapeutic limit. Therefore, curative antitumor regimens will likely involve several treatment modalities with nonoverlapping toxicities. One such treatment modality that has already been demonstrated to result in potentiated antitumor effectiveness when combined with chemotherapeutics is immunotherapy. Among all cytokines tested, Interleukin-12 (IL-12) seems to have the strongest antitumor activity. 3, 4 Interleukin-12 -a cytokine with a unique structure, com- posed of two co-valently joined subunits of 35 (p35) and 40 (p40) kDa and secreted mainly by macrophages and dendritic cells is known to play an immunoregulatory role by promoting cell-mediated immunity. 5, 6 IL-12 stimulates proliferation and cytotoxic activity of T and NK cells. 7, 8 It is one of the most potent endogenous inducers of IFN-␥ secretion from T and NK cells 8, 9 and promotes differentiation of Th1 cells. 10 Until recently, IL-12 has been mainly investigated in solid tumor models. 11, 12 However, there are several observations that indicate the potential therapeutic activity of this cytokine in non-solid malignancies. IL-12 with low-dose IL-2 is inducing high lytic activity of NK cells against human leukemia cells in vitro. 13 It induces lesion regression and cytotoxic T cell responses in cutaneous T cell lymphomas in humans 14 and preserves graft-versus-leukemia effects with concomitant inhibition of graft-versus-host reaction in mice. 15 Moreover, it has recently been reported by Dunussi-Joannopoulos et al 16 that systemic administration of IL-12 significantly delays the growth of acute myeloid leukemia (AML) cells inoculated into mice.
We have previously demonstrated that the antileukemic effectiveness of IL-12 might be dramatically improved by its combined applications with doxorubicin, but not with taxol or cyclophosphamide. 17 Moreover, cisplatin and mitoxantrone potentiated, in an additive manner, antileukemic activity of IL-12. 17, 18 In our further studies we decided to combine IL-12 with 5-FU, a chemotherapeutic that demonstrates several interesting immunomodulatory activities, 19 and is one of the few successfully used in clinic in combination with biological response modifiers. 19, 20 
Materials and methods

Drugs
Recombinant murine IL-12 (specific activity 2.8 × 10 6 U/mg) was kindly provided by Genetics Institute (Boston, MA, USA). IL-12 was diluted with 0.1% BSA (Sigma, St Louis, MO, USA) in Dulbecco's phosphate buffered saline (PBS) (Gibco BRL, Paisley, UK). 5-FU was purchased from Polfa (Warsaw, Poland). It was diluted in 0.9% NaCl to obtain appropriate concentration. Silica (0.5-10 m with 80% between 1 and 5 m) was purchased from Sigma.
Mice and tumor cells
Female (C57BL6 × DBA/2) mice, hereafter called B6D2F 1 , 6-8 weeks old, were used. Breeding pairs were obtained from the Inbred-Mice Breeding Center of the Institute of Immunology and Experimental Medicine, Wroc aw, Poland. Mice were bred in a local animal facility and kept in conventional conditions with unlimited access to food and water during experiments. Six-to 8-week-old C.B-17 scid/scid mice were kindly obtained from Professor M Kurpisz (Human Genetics Institute, Polish Academy of Sciences, Poznań , Poland). These animals were housed under specific pathogen-free conditions. All experiments with animals were performed in accordance with the guidelines approved by the Ethical Committee of the Medical University of Warsaw.
L1210 leukemia cells were maintained in RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf serum (FCS), antibiotics, 2-mercaptoethanol (50 m) and lglutamine (2 mm) (all from Gibco BRL), hereafter referred to as culture medium. Cells were maintained in 25-cm 2 tissue flasks (Corning, NY, USA) at 37°C in a humidified atmosphere of 5% CO 2 and passaged every 3-4 days.
In vivo experiments
For the in vivo experiments, L1210 cells were harvested from culture flasks, washed twice in RPMI-1640 medium and adjusted to a concentration of 1 × 10 6 cells/ml of PBS. Mice were inoculated i.p. on day 0 with 1 × 10 5 cells in 100 l PBS. To investigate the effects of IL-12, leukemia-bearing mice were injected i.p. with IL-12 at a dose of 0.1 g per injection in the volume of 100 l for 7 consecutive days, starting from day 4 after tumor cells inoculation. Injections of 100 l 0.1% BSA-PBS were given as controls for the cytokine treatment. 5-FU was administered as a single i.p. injection of 10 l of chemotherapeutic dilution per 1 g of mouse body weight on day 4 following leukemia cell inoculation at a dose of 50 mg/kg. Appropriate volume of saline was given as controls for the chemotherapy treatment. During the experiments, mice were observed daily for survival. 
In vivo lymphocyte depletion studies
In vivo macrophage-depletion experiment
All mice were inoculated on day 0 with 1 × 10 5 L1210 leukemia cells. The treatment with IL-12 and/or 5-FU was applied as described above. Injections of silica were used to deplete activated macrophages in vivo. 21 For these studies, mice received 100 l of PBS or 25 mg silica in 100 l PBS injected i.p. on days −1, 3, 5 and 7 (day 0 was the day of L1210 cells inoculation).
Determination of endogenous IFN-␥ in mouse serum
Mice were inoculated i.p. with IL-12 (100 ng/dose for 3, 5 or 7 consecutive days) and/or 5-FU (single injection of 50 mg/kg). In an additional experiment mice were inoculated i.p. on day 0 with 1 × 10 5 L1210 leukemia cells and were treated with IL-12 (100 ng for 5 consecutive days) or 5-FU (single injection of 50 mg/kg). Then, at least 4 h after the last injection of IL-12, mice were bled (under ether anesthesia) and serum samples were collected. Concentrations of IFN-␥ in serum samples were measured using an ELISA kit (Duo-Set) purchased form Genzyme (Cambridge, MA, USA) according to the manufacturer's instructions.
MTT assay
The cytostatic and/or cytotoxic effects on L1210 cells were tested in a standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, as described previously. 
Presentation of data and statistical analysis
Kaplan-Meier plots were generated, and survival time of animals was analyzed for significance by log-rank survival analysis. Serum levels of IFN-␥ were analyzed using Student's t-test. Significance was defined as a two-sided P Ͻ 0.05.
Results
Effects of IL-12 combined with 5-FU on the survival of mice inoculated with 1 × 10 5 L1210 cells
Intraperitoneal inoculation of mice with 1 × 10 5 L1210 leukemia cells results in a rapid development of ascites followed by a death of all animals within 10 days. Mice inoculated with only 1 × 10 3 L1210 cells invariably die within 12 days. It has been determined that mice that survive for more than 60 days after inoculation of L1210 cells might be regarded as longterm survivors.
In our previous studies we have observed that the combination treatment with doxorubicin and IL-12 administered at a dose of 100 ng/day is an optimal antitumor regimen resulting in 100% of long-term survivors among mice inoculated with 1 × 10 5 leukemia cells. 17, 23 During the search for other chemotherapeutics with immunomodulatory activities that are capable of producing substantial antitumor effects when administered at nontoxic doses in combination with IL-12 we have found that simultaneous administration of IL-12 and 5-FU (single injection of 50 mg/kg) results in 70% of long-
Figure 1
Influence of treatment with IL-12 and 5-FU on the survival of mice inoculated with 1 × 10 5 L1210 cells. The treatment was started on day 4 after inoculation with leukemia cells. IL-12 was administered daily at a dose of 100 ng (a) or 170 ng (b) for 7 consecutive days, 5-FU was given on day 4 as a single injection of 50 mg/kg. Mice were observed for survival up to day 60 following inoculation of the leukemia cells. Data presented in (a) have been pooled from two independent experiments, as the results of them were in agreement. There were 14 (a) or 6-7 (b) mice in each group.
# P Ͻ 0.01, log rank survival analysis vs all other groups.
term survivors (Figure 1a ). The dose of IL-12 used in the combination therapy was 100 ng/day as in our earlier studies. However, the specific activity of this batch of IL-12 was slightly lower than that in our previous studies (2.7 U/mg protein vs 4.2 U/mg protein). Therefore, we were interested whether administration of IL-12 at the dose of 170 ng/day, corresponding to the same unit dose as used in our earlier experiments, would result in comparable antitumor efficacy. It turned out that indeed by using 170 ng/day we could observe 100% of animals surviving for more than 60 days (Figure 1b) . Some of these animals were left for rechallenge experiments and they were leukemia-free for at least another 100 days. As many as 13 of 14 (93%) of the long-term survivors reinoculated intraperitoneally with 1 × 10 5 L1210 leukemia cells on day 61 following initial inoculation of leukemia cells rejected tumor cells (Table 1) . We were also interested whether this effect is a result of a prolonged activation of the immune system, extending to over 60 days or whether this is a long-term immunologic memory, capable of protecting cured animals for a much longer time. The complete protective effect was observed in all animals even after 150 days following treatment. To verify whether this is only local protection in the peritoneal cavity we inoculated long-term survivors intravenously and again we observed rejection of leukemia The rechallanges were done using 1 × 10 5 or 1 × 10 6 L1210 cells, administered 61 or 150 days after first inoculation of mice with leukemia cells. Leukemia cells were inoculated either intraperitoneally or intravenously. All of the age-matched controls died within 7 or 9 days after inoculation with 1 × 10 6 or 1 × 10 5 L1210 cells, respectively.
Leukemia cells. In all of these rechallenge experiments we used agematched controls that uniformly died within 10 days after inoculation of L1210 cells (Table 1) .
To investigate the strength of these protective effects we inoculated long-term survivors and control mice with 1 × 10 6 L1210 cells. This time, controls succumbed within 7 days following inoculation of leukemia cells but 100% of long-term survivors survived for another 60 days without any sign of leukemia (Table 1) .
To determine the cellular requirements for successful IL-12 + 5-FU therapy, survival studies were conducted in NKdeficient scid/scid mice and in animals depleted of particular leukocyte populations. In these experiments a lower dose of IL-12 (100 ng/day) was used as we wanted to assess potentially positive or negative influence of the depletions on the effectiveness of our therapy.
Antileukemic effects of the combination treatment in scid/scid mice and NK1.1 cells-depleted mice
Several reports indicate that the antitumor effects of IL-12 treatment result from activation of NK cells. [24] [25] [26] [27] To verify whether the striking antileukemic efficacy of IL-12 + 5-FU combination is dependent on the presence and activity of these cell populations we have undertaken experiments in scid/scid mice that lack T and B cells but have normal NK cells. Six-to 8-week-old scid/scid mice were inoculated i.p. with 1 × 10 5 L1210 leukemia cells. Four days later IL-12 and/or 5-FU were administered in the same treatment schedule as described above. Although both IL-12 and 5-FU when administered alone exerted a slight, albeit significant antitumor effects as compared with controls, there was no potentiation of the antileukemic efficacy in animals treated with both agents simultaneously (Figure 2a) . To confirm theses observations in another model we evaluated the antileukemic response in mice depleted of NK1.1 cells. Administration of IL-12 and 5-FU resulted in long-term survival in 60% of animals. However, there was no abrogation of these antileukemic effects in mice depleted of NK1.1 cells (Figure 2b) .
These results indicate that the presence of NK cells is not sufficient to induce antitumor effects in L1210 leukemia and together with the results of the rechallenge experiments imply that the observed efficacy of the treatment is dependent on the specific arm of the immune system. (Figure 3 ). 
Effects of treatment with IL-12 and 5-FU in leukemia-
Effects of treatment with IL-12 and 5-FU in macrophage-depleted leukemia-bearing mice
Mice were injected with silica to deplete activated peritoneal macrophages on days −1, 3 and 7 (on day 0 mice were inoculated with 1 × 10 5 L1210 cells). As shown in Figure 4 , depletion of macrophages did not significantly shorten the survival time of untreated controls in comparison with nonmacrophage-depleted controls (mice in both groups died between days 7 and 10 after leukemia cell inoculation). However, macrophage depletion almost completely reduced the anti-leukemic effectiveness of the combined chemo-immunotherapy indicating that the presence of macrophages is necessary for the observed effects.
Serum levels of endogenous IFN-␥ in mice treated with IL-12 and/or 5-FU
One of the properties of IL-12 is its ability to induce the secretion of IFN-␥. 28 Therefore, we decided to measure serum levels of this cytokine following IL-12 and/or 5-FU treatment in mice inoculated with 1 × 10 5 L-1210 leukemia cells. Since both controls and single-agent treated animals rapidly develop ascites and die of leukemia we were unable to perform a longer-lasting analysis of IFN-␥ secretion and decided to measure secretion of this cytokine in normal (non-leukemic) mice as well.
As shown in Table 2 administration of five doses of IL-12 (100 ng/dose) into leukemia-bearing mice significantly increased the serum concentration of IFN-␥ as compared with controls. Interestingly, and in contrast to our previous observations in mice treated with IL-12 and doxorubicin, simultaneous administration of IL-12 and 5-FU resulted in decreased secretion of IFN-␥, as compared to IL-12-treated animals.
In normal, non-leukemia-bearing mice, there was a slight induction of IFN-␥ secretion by 5-FU and significant induction by IL-12 (as compared with controls), but we could not observe any further potentiation of these effects in animals treated with both agents simultaneously ( Figure 5 ).
In vitro cytostatic/cytotoxic effects of 5-FU and/or IFN-␥
In previous studies it has been reported that IFN-␥ is exerting synergistic cytostatic/cytotoxic effects with several chemotherapeutics, including 5-FU, on tumor cells. [29] [30] [31] As demonstrated in Table 2 , there is still an increased secretion of IFN-␥ in animals treated with combined chemo-immunotherapy as compared with controls. It is possible therefore, that the observed antileukemic effects might, at least partly result from direct action of this cytokine and 5-FU on leukemia cells. To investigate this mechanism we have performed an in vitro Table 2 Serum levels of endogenous IFN-␥ in leukemia-bearing mice following treatment with 5-FU and IL-12 
Leukemia
Figure 5
Serum levels of endogenous IFN-␥ in normal mice following treatment with 5-FU and IL-12. Normal, non-leukemia-bearing animals were treated with IL-12 (100 ng per injection for 7 consecutive days) and/or 5-FU (single injection of 50 mg/kg). IFN-␥ concentrations were determined as described in Materials and methods. *P Ͻ 0.05 as compared with controls (Student's t-test).
MTT assay that enables evaluation of the direct influence of these two agents on tumor cells. Although both 5-FU and IFN-␥ exerted dose-dependent antileukemic effects in vitro, we did not observe any further potentiation of the cytotostatic/ cytotoxic effects when these two agents were combined together ( Figure 6 ).
Discussion
It has been well-established that chemo-immunotherapy using cytotoxic drugs and several cytokines offers a new approach
Figure 6
Response of L1210 leukemia cells to combinations of IFN-␥ and/or 5-FU in vitro. L1210 cells were exposed for 24 h to various concentrations of IFN-␥ and/or 5-FU. Cytostatic/cytotoxic effects were tested in a standard MTT assay (as described in Material and methods). Data are presented as a relative viability (% of untreated controls). Each bar represents mean ± s.d.
to increase the therapeutic index in the treatment of neoplastic diseases. Therefore, identification of appropriate chemotherapeutics synergizing with IL-12 seems to be one of the unquestionable ways to make the application of this potent antitumor agent to the clinical practice more successful.
Because of the multiple biologic effects assigned to IL-12 the mechanisms of its antitumor effects are difficult to pinpoint. The mechanisms of antitumor activity of IL-12 seem to involve predominantly stimulation of cytotoxicity, proliferation and IFN-␥ secretion from T and NK cells, indirect activation of macrophages and interference with angiogenesis. 3, 4, [32] [33] [34] In numerous tumor models IL-12 apparently induces tumor regression through induction of IFN-␥ secretion. 4, 27 However, administration of IL-12 into nude mice bearing Renca renal cell carcinoma resulted in decreased antitumor activity despite about 10-fold stronger induction of IFN-␥. 32 In the present study we could observe a significant induction of IFN-␥ production by IL-12 that was nonetheless insufficient for eradication of leukemia cells. Administration of IL-12 together with 5-FU did not result in any further increase in the production of IFN-␥. This is in contrast to our previous observations in the L1210 leukemia model when mice were treated with a combination of IL-12 and doxorubicin and we could observe a strong induction of IFN-␥ secretion after chemo-immunotherapy. 17 These results indicate that the combinations of 5-FU with IL-12 and doxorubicin with IL-12, although equally effective in eradication of leukemia cells, seem to induce different antitumor mechanisms. Indeed, although we could observe a pronounced potentiation of doxorubicin-mediated cytostatic/cytotoxic effects against L1210 cells by IFN-␥ in vitro, there was no such effect in the case of 5-FU combined with this cytokine. Altogether strong potentiation of antileukemic effects of 5-FU by IL-12 cannot be fully explained by the direct cytostatic/cytotoxic effects of IL-12-induced IFN-␥ and 5-FU on leukemia cells. Moreover, taking into account the toxicities observed during treatments inducing the secretion of substantial amounts of IFN-␥, 35 it might be expected that the combination of IL-12 and 5-FU would be relatively safe. Indeed, we could not observe any gross toxicity in treated animals, such as weight loss, diarrhea, hunched habitus, etc.
5-FU, is one of the chemotherapeutics known to exert several immunomodulatory effects. It has been demonstrated that 5-FU augments mouse LAK cell activity 20 and increases antitumor immunity associated with cytokine production. 19 IL-12 was initially recognized as a natural killer cell stimulatory factor (NKSF), a name stemming from its ability to stimulate the cytotoxicity of natural killer cells. 7, 8 It was therefore not expected to reveal that the antileukemic effects observed during the combined treatment with IL-12 and 5-FU were completely independent of NK cells. Numerous studies with IL-12 reveal however, that the mechanisms of antitumor effects of this cytokine are tumor-type dependent. For example, in the Colon-26 model of colon adenocarcinoma, the antitumor effects are dependent on the presence and activity of CD8 + cells, and might even be potentiated after elimination of CD4 + cells. 36 NK cells are dispensable for eradication of these tumors, but seem to be of utmost importance in elimination of B16 melanoma lung metastases. 26 In Renca renal cell carcinoma the complex antitumor effects involve T cells and macrophages. 37 Moreover, regression of hepatic metastases of Renca carcinoma involve intensive infiltration of tumor parenchyma by macrophages and neutrophils. 38 Therefore, depending on the tumor system employed, T cells, NK cells, macrophages and/or even neutrophils could be involved in the antitumor immune responses generated by IL-12.
The antileukemic effects of the combined chemo-immunotherapy in this model represent an example of the cooperation between the innate and specific immune responses. Since most tumor types do not express MHC class II molecules and therefore are incapable of direct antigen presentation to CD4 + cells, it is conceivable that antigen presenting cells are necessary for tumor antigen presentation in an indirect manner. Indeed, the antileukemic effects are abrogated by either CD4 + T cells depletion or by removal of peritoneal macrophages. The latter cells might be responsible for initial engulfment of dying leukemia cells, and after appropriate IFN-␥ stimulation (with IFN-␥ being induced by IL-12) might present tumor antigens to CD4 + cells. Not many studies were done on the combination tumor chemo-immunotherapy with IL-12. 17, 18, 23, [39] [40] [41] The mechanisms of the observed effects were not investigated in detail, either. Elucidation of these mechanisms is of importance, as they would enable further optimization of the treatment schedules. Our studies indicate that the antileukemic effects of 5-FU and IL-12 in the murine L1210 leukemia model involve activation of both innate and adaptive immunity. The cooperation between macrophages and T cells seems to be extremely important in the development of the curative immunity as elimination of either of these leukocyte populations is reducing or completely abrogating the effectiveness of treatment.
Although 5-FU is not used in the clinical setting in the treatment of leukemia, the striking effects observed in these studies encourage us to reconsider the potential use of 5-FU in combination with interleukin-12 in the treatment of at least some forms of leukemia.
In conclusion, we show that combined chemo-immunotherapy with 5-FU and IL-12 induces a strong antileukemic response that is capable of producing long-term survival in up to 100% of mice. Most of the long-term survivors are capable of rejecting re-inoculated L1210 cells. This effect is specific, long-lasting and efficient even after rechallenge with 1 × 10 6 L1210 cells. The effectiveness of the combination chemoimmunotherapy in this system can be attributed to the activation of the macrophages and T lymphocytes. Results of these experiments revealed that for the optimal antileukemic efficacy of the combination treatment presence of both CD4 + and CD8
+ lymphocytes is necessary. However, these cells are not sufficient for the maximal antitumor effects since the presence of these cells in animals depleted of macrophages does not warrant the elimination of leukemic cells. Quite unexpectedly, the presence of NK cells seems to be dispensable for the antileukemic effects of the combination treatment in this model. There is also no indication of the significant stimulation of the humoral antileukemic response.
